Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
CD30-targeted autologous CAR-T cells
- Development stage
- Unknown
- Lead developer
- Wuhan Bio-Raid Biotechnology
- Modality
- CAR-T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies
- Administration
- Intravenous
01
Overview
CD30-targeted autologous CAR-T cells refer to a class of chimeric antigen receptor (CAR) T-cell therapies engineered to target the CD30 antigen (TNFRSF8), which is predominantly expressed on the surface of malignant cells in Hodgkin lymphoma and anaplastic large cell lymphoma. This autologous approach involves harvesting a patient's own T cells and genetically modifying them to express a CAR specific for CD30. Wuhan Boruida Biotechnology is one of the developers advancing this modality, with a specific candidate currently in Phase 1 clinical trials in China for relapsed or refractory CD30-positive hematologic malignancies. The therapy aims to provide a targeted cytotoxic response against tumor cells while minimizing impact on healthy tissues with low CD30 expression.
- Other names
- CD30 CAR-TCD-30 CAR-TCD 30 CAR-TCD30-directed autologous CAR-T cellsCD-30-directed autologous CAR-T cellsCD 30-directed autologous CAR-T cells
02
Targets
CD30 (CD30 antigen)
Beyond the preview
Go deeper on CD30-targeted autologous CAR-T cells.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on CD30-targeted autologous CAR-T cells.